December 20, 2024
Dear Alliance Researchers and Colleagues,
As we close out another remarkable year, I want to extend my heartfelt gratitude to each of you for all you do to change lives and advance the future of cancer care. Your unique contributions—whether through leadership in scientific research, patient advocacy, or the development of collaborative strategies—are at the heart of our collective success. I am incredibly proud of the work we’ve
Palbociclib is the first CDK4/6 inhibitor to show benefit in a large phase III trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
December 12, 2024
Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBR
December 11, 2024
Perioperative versus adjuvant systemic therapy in patients with resectable non-small cell lung cancer - PROSPECT LUNG (CTIU2317-A082304-S2402)
Daniel Morgensztern, MD, of Washington University, Siteman Cancer Center, and Raid Aljumaily, MD, of University of Oklahoma, OU Health Stephenson Cancer Center, co-lead the PROSPECT-Lung phase III trial to compare standard therapy given after surgery (adjuva
